Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support. (se deschide o fereastră nouă)

Al-Nawakil C, Quarre MC, Heshmati F, Deau B, Park S, Dreyfus F, Bouscary D, Tamburini J.

Sursă‎: Br J Haematol 2013;161(5):738-40.

Index‎: PubMed 23480574

DOI‎: 10.1111/bjh.12284

https://www.ncbi.nlm.nih.gov/pubmed/23480574 (se deschide o fereastră nouă)

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. (se deschide o fereastră nouă)

Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ

Sursă‎: Haematologica 2021;106(4):1148-57.

Index‎: PubMed 32499239

DOI‎: 10.3324/haematol.2020.251900

https://www.ncbi.nlm.nih.gov/pubmed/32499239 (se deschide o fereastră nouă)

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. (se deschide o fereastră nouă)

Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J.

Sursă‎: Cancer 2008;113(6):1338-43.

Index‎: PubMed 18629842

DOI‎: 10.1002/cncr.23718

https://www.ncbi.nlm.nih.gov/pubmed/18629842 (se deschide o fereastră nouă)

Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia. (se deschide o fereastră nouă)

Berthelot-Richer M, Boilard B, Morin A, Bolduc B, Beauregard P, Kotb R.

Sursă‎: Transfusion 2012;52(4):739-41.

Index‎: PubMed 22082044

DOI‎: 10.1111/j.1537-2995.2011.03382.x

https://www.ncbi.nlm.nih.gov/pubmed/22082044 (se deschide o fereastră nouă)

The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. (se deschide o fereastră nouă)

Bhatia M, Davenport V, Cairo MS.

Sursă‎: Leuk Lymphoma 2007;48(1):9-15.

Index‎: PubMed 17325843

DOI‎: 10.1080/10428190600909115

https://www.ncbi.nlm.nih.gov/pubmed/17325843 (se deschide o fereastră nouă)

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. (se deschide o fereastră nouă)

Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Kamel YM.

Sursă‎: BMC Cancer 2013;13:121.

Index‎: PubMed 23497336

DOI‎: 10.1186/1471-2407-13-121

https://www.ncbi.nlm.nih.gov/pubmed/23497336 (se deschide o fereastră nouă)

Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. (se deschide o fereastră nouă)

Demeter J, Istenes I, Fodor A, Paksi M, Dombi P, Valasinyószki E, Csomor J, Matolcsy A, Nagy ZG.

Sursă‎: Pathol Oncol Res 2011;17(1):141-3.

Index‎: PubMed 20628840

DOI‎: 10.1007/s12253-010-9276-4

https://www.ncbi.nlm.nih.gov/pubmed/20628840 (se deschide o fereastră nouă)

Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient. (se deschide o fereastră nouă)

Duic JP, Grewal J, McConie K, Staszewski H, Haas J, Kesari S.

Sursă‎: J Neurooncol 2012;106(2):427-9.

Index‎: PubMed 21833801

DOI‎: 10.1007/s11060-011-0675-5

https://www.ncbi.nlm.nih.gov/pubmed/21833801 (se deschide o fereastră nouă)

Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. (se deschide o fereastră nouă)

Ellis M, Zwaan F, Hedström U, Poynton C, Kristensen J, Jumaa P, Wassell J, al-Ramadi B.

Sursă‎: Lancet 2003;361(9354):275-80.

Index‎: PubMed 12559860

https://www.ncbi.nlm.nih.gov/pubmed/12559860 (se deschide o fereastră nouă)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (se deschide o fereastră nouă)

Ford PA, Grant SJ, Mick R, Keck G.

Sursă‎: J Clin Oncol 2015;33(15):1674-9.

Index‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (se deschide o fereastră nouă)

Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors. (se deschide o fereastră nouă)

Gao Y, Liu Q, Shen Y, Li Y, Shao K, Ye B, Shen Y, Zhou Y, Wu D

Sursă‎: Platelets. 2022 3;33(7):1024-1030.

Index‎: PubMed 35040375

DOI‎: 10.1080/09537104.2022.2026910

https://pubmed.ncbi.nlm.nih.gov/35040375/ (se deschide o fereastră nouă)

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. (se deschide o fereastră nouă)

Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Hu K, Woodard P, Yang AS, Kantarjian HM.

Sursă‎: Cancer 2014;120(12):1838-46.

Index‎: PubMed 24706489

DOI‎: 10.1002/cncr.28663

https://www.ncbi.nlm.nih.gov/pubmed/24706489 (se deschide o fereastră nouă)

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. (se deschide o fereastră nouă)

Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J.

Sursă‎: Leuk Lymphoma 2013;54(2):321-8.

Index‎: PubMed 22906162

DOI‎: 10.3109/10428194.2012.713477

https://www.ncbi.nlm.nih.gov/pubmed/22906162 (se deschide o fereastră nouă)

Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. (se deschide o fereastră nouă)

Gudbrandsdottir S, Frederiksen H, Hasselbalch H.

Sursă‎: Platelets 2012;23(6):423-9.

Index‎: PubMed 22185370

DOI‎: 10.3109/09537104.2011.634931

https://www.ncbi.nlm.nih.gov/pubmed/22185370 (se deschide o fereastră nouă)

Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial. (se deschide o fereastră nouă)

Han TT, Xu LP, Liu DH, Liu KY, Wang FR, Wang Y, Yan CH, Chen YH, Sun YQ, Ji Y, Wang JZ, Zhang XH, Huang XJ.

Sursă‎: Ann Hematol 2015;94(1):117-28.

Index‎: PubMed 25069650

DOI‎: 10.1007/s00277-014-2158-1

https://www.ncbi.nlm.nih.gov/pubmed/25069650 (se deschide o fereastră nouă)

The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. (se deschide o fereastră nouă)

Jeong JY, Levine MS, Abayasekara N, Berliner N, Laubach J, Vanasse GJ.

Sursă‎: J Hematol Oncol 2015;8:37.

Index‎: PubMed 25886818

DOI‎: 10.1186/s13045-015-0136-2

https://www.ncbi.nlm.nih.gov/pubmed/25886818 (se deschide o fereastră nouă)

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. (se deschide o fereastră nouă)

Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP.

Sursă‎: J Clin Oncol 2010;28(3):437-44.

Index‎: PubMed 20008626

DOI‎: 10.1200/JCO.2009.24.7999

https://www.ncbi.nlm.nih.gov/pubmed/20008626 (se deschide o fereastră nouă)

The use of simple patient blood management strategies as an alternative to platelet and red cell transfusion in autologous stem cell transplant. (se deschide o fereastră nouă)

Locantore-Ford P, Grant SJ, Keck G.

Sursă‎: Blood 2013;122(21):2140.

https://www.bloodjournal.org/content/122/21/2140 (se deschide o fereastră nouă)

The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. (se deschide o fereastră nouă)

Loo M, Beguin Y.

Sursă‎: Blood 1999;93(10):3286-93.

Index‎: PubMed 10233880

https://www.ncbi.nlm.nih.gov/pubmed/10233880 (se deschide o fereastră nouă)

A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia. (se deschide o fereastră nouă)

Miao J, Leblebjian H, Scullion B, Parnes A

Sursă‎: Am J Hematol 2018;93(4):E86-E88.

Index‎: PubMed 29274130

DOI‎: 10.1002/ajh.25022

https://www.ncbi.nlm.nih.gov/pubmed/29274130 (se deschide o fereastră nouă)

Pharmacological therapies to minimise platelet transfusion. (se deschide o fereastră nouă)

Norfolk DR, Seghatchian J.

Sursă‎: Transfus Sci 2000;22(3):149-53.

Index‎: PubMed 10831916

https://www.ncbi.nlm.nih.gov/pubmed/10831916 (se deschide o fereastră nouă)

Romiplostim for management of chemotherapy-induced thrombocytopenia. (se deschide o fereastră nouă)

Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G.

Sursă‎: Support Care Cancer 2014;22(5):1217-22.

Index‎: PubMed 24414994

DOI‎: 10.1007/s00520-013-2074-2

https://www.ncbi.nlm.nih.gov/pubmed/24414994 (se deschide o fereastră nouă)

Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. (se deschide o fereastră nouă)

Pathak S, Roth M, Verma A, Steidl U.

Sursă‎: Expert Opin Drug Metab Toxicol 2013;9(12):1667-75.

Index‎: PubMed 24215532

DOI‎: 10.1517/17425255.2013.858119

https://www.ncbi.nlm.nih.gov/pubmed/24215532 (se deschide o fereastră nouă)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (se deschide o fereastră nouă)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Sursă‎: Leuk Lymphoma. 2019;60(9):2324-7.

Index‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (se deschide o fereastră nouă)

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. (se deschide o fereastră nouă)

Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A.

Sursă‎: Lancet Haematol 2015;2(10):e417-26.

Index‎: PubMed 26686043

https://www.ncbi.nlm.nih.gov/pubmed/26686043 (se deschide o fereastră nouă)

Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. (se deschide o fereastră nouă)

Poon LM, Di Stasi A, Popat U, Champlin RE, Ciurea SO.

Sursă‎: Am J Blood Res 2013;3(3):260-4.

Index‎: PubMed 23997988

https://www.ncbi.nlm.nih.gov/pubmed/23997988 (se deschide o fereastră nouă)

Safety and efficacy of eltrombopag in post-hematopoietic stem cell transplantation (HSCT) thrombocytopenia. (se deschide o fereastră nouă)

Raut SS, Shah SA, Sharanangat VV, Shah KM, Patel KA, Anand AS, Talati SS, Panchal HP, Patel AA, Parikh SK, Shukla SN.

Sursă‎: Indian J Hematol Blood Transfus 2015;31(4):413-5.

Index‎: PubMed 26306064

DOI‎: 10.1007/s12288-014-0491-0

https://www.ncbi.nlm.nih.gov/pubmed/26306064 (se deschide o fereastră nouă)

Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. (se deschide o fereastră nouă)

Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, George JN, Vesely SK.

Sursă‎: Blood 2010;116(12):2127-33.

Index‎: PubMed 20530792

DOI‎: 10.1182/blood-2010-03-276691

https://www.ncbi.nlm.nih.gov/pubmed/20530792 (se deschide o fereastră nouă)

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. (se deschide o fereastră nouă)

Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U.

Sursă‎: Blood 2012;120(2):386-94.

Index‎: PubMed 22627766

DOI‎: 10.1182/blood-2011-12-399667

https://www.ncbi.nlm.nih.gov/pubmed/22627766 (se deschide o fereastră nouă)

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. (se deschide o fereastră nouă)

Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D.

Sursă‎: Cancer 2011;117(5):992-1000.

Index‎: PubMed 20945323

DOI‎: 10.1002/cncr.25545

https://www.ncbi.nlm.nih.gov/pubmed/20945323 (se deschide o fereastră nouă)

Romiplostim treatment of chemotherapy-induced thrombocytopenia. (se deschide o fereastră nouă)

Soff GA, Miao Y, Bendheim G, Batista J, Mones JV, Parameswaran R, Wilkins CR, Devlin SM, Abou-Alfa GK, Cercek A, Kemeny NE, Sarasohn DM, Mantha S

Sursă‎: J Clin Oncol 2019;37(31):2892-8.

Index‎: PubMed 31545663

DOI‎: 10.1200/JCO.18.01931

https://www.ncbi.nlm.nih.gov/pubmed/31545663 (se deschide o fereastră nouă)

Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. (se deschide o fereastră nouă)

Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B.

Sursă‎: Blood 2000;95(9):2983-9.

Index‎: PubMed 10779449

https://www.ncbi.nlm.nih.gov/pubmed/10779449 (se deschide o fereastră nouă)

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. (se deschide o fereastră nouă)

Svensson T, Chowdhury O, Garelius H, Lorenz F, Saft L, Jacobsen SE, Hellström-Lindberg E, Cherif H.

Sursă‎: Eur J Haematol 2014;93(5):439-45.

Index‎: PubMed 24853277

DOI‎: 10.1111/ejh.12383

https://www.ncbi.nlm.nih.gov/pubmed/24853277 (se deschide o fereastră nouă)

Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. (se deschide o fereastră nouă)

Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, Kim SW, Tanosaki R, Fukuda T.

Sursă‎: Biol Blood Marrow Transplant 2016;22(5):919-24.

Index‎: PubMed 26785333

DOI‎: 10.1016/j.bbmt.2016.01.018

https://www.ncbi.nlm.nih.gov/pubmed/26785333 (se deschide o fereastră nouă)

Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. (se deschide o fereastră nouă)

Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J, Kurzrock R.

Sursă‎: Ann Oncol 2005;16(1):139-45.

Index‎: PubMed 15598951

DOI‎: 10.1093/annonc/mdi007

https://www.ncbi.nlm.nih.gov/pubmed/15598951 (se deschide o fereastră nouă)

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. (se deschide o fereastră nouă)

Wang ES, Lyons RM, Larson RA, Gandhi S, Liu D, Matei C, Scott B, Hu K, Yang AS.

Sursă‎: J Hematol Oncol 2012;5:71.

Index‎: PubMed 23190430

DOI‎: 10.1186/1756-8722-5-71

https://www.ncbi.nlm.nih.gov/pubmed/23190430 (se deschide o fereastră nouă)

Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use. (se deschide o fereastră nouă)

Wilkins CR, Ortiz J, Gilbert LJ, Yin S, Mones JV, Parameswaran R, Mantha S, Soff GA

Sursă‎: Res Pract Thromb Haemost. 2022;6(3):e12701.

Index‎: PubMed 35582038

DOI‎: 10.1002/rth2.12701

https://pubmed.ncbi.nlm.nih.gov/35582038/ (se deschide o fereastră nouă)

Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. (se deschide o fereastră nouă)

Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U.

Sursă‎: Blood 2009;114(18):3899-908.

Index‎: PubMed 19710504

DOI‎: 10.1182/blood-2009-04-219493

https://www.ncbi.nlm.nih.gov/pubmed/19710504 (se deschide o fereastră nouă)